Indefinite Delivery Contract SPE2DR25D3012

The Indefinite Delivery Contract (IDC) SPE2DR25D3012 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $999,999,999 contract, which runs through December 2026, establishes AmerisourceBergen as a Pharmaceutical Prime Vendor to provide a comprehensive range of pharmaceutical products and medical supplies in support of military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The contract aims to ensure the DLA, Department of Defense, United States Coast Guard, and other government agencies have reliable access to vital pharmaceuticals during normal operations, contingencies, and disasters. The contract utilizes a Lowest Price Technically Acceptable (LPTA) evaluation methodology, with the government reserving the option to conduct a reverse auction to obtain the best possible distribution fees.

The IDC was awarded as part of the DLA Troop Support Medical's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) procurement, which seeks to establish multiple regional contracts to support DoD and other federal healthcare customers. The unrestricted, fully competitive solicitation is expected to have an estimated total value of $30.3 billion and will award at least three different contractors across the North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet regions. By diversifying the supplier base, the government aims to increase the resiliency and access to essential pharmaceuticals during times of contingency or natural disasters.